ArticleGenome medicine2017
Functional implications of microbial and viral gut metagenome changes in early stage L-DOPA-naïve Parkinson's disease patients.
Article in Genome medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 370 papers, 10 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
370 citing papers in PubMed, 10 syntheses or guidelines pooled it, 619 citations in OpenAlex.
- Faecalibacterium prausnitzii and Akkermansia muciniphila: driving the multiple sclerosis-a systematic review.Antonie van Leeuwenhoek · 2026Pooled it
- Global research trends in enteric nervous system and gut microbiota: a bibliometric analysis (2005-2025).Frontiers in cellular and infection microbiology · 2026Pooled it
- Gut microbiota signatures in mild cognitive impairment: a scoping review of microbial taxa and clinical implications.Frontiers in microbiology · 2026Pooled it
- Beyond bacteria: a multi-omics view of the gut-brain axis in Parkinson's disease.Frontiers in cellular and infection microbiology · 2026Pooled it
- Machine learning-based meta-analysis reveals gut microbiome alterations associated with Parkinson's disease.Nature communications · 2025Pooled it
- The two-directional prospective association between inflammatory bowel disease and neurodegenerative disorders: a systematic review and meta-analysis based on longitudinal studies.Frontiers in immunology · 2024Pooled it
- Gut Microbiota Composition in Patients with Neurodegenerative Disorders (Parkinson's and Alzheimer's) and Healthy Controls: A Systematic Review.Nutrients · 2023Pooled it
- Changes in Gut Microbiota and Multiple Sclerosis: A Systematic Review.International journal of environmental research and public health · 2023Pooled it
- Gut bacterial profiles in Parkinson's disease: A systematic review.CNS neuroscience & therapeutics · 2023Pooled it
- What Are the Key Gut Microbiota Involved in Neurological Diseases? A Systematic Review.International journal of molecular sciences · 2022Pooled it
- Trial
- GutMIND: A multi-cohort machine learning framework for integrative characteristics of the microbiota-gut-brain axis in neuropsychiatric disorders.Gut microbes · 2026Article
- Bacterial constipation: Mucin-degrading intestinal commensal bacteria cause constipation.Gut microbes · 2026Article
- Bridging the gap:Gut microbes · 2026Review
- Article
- The microbiota-proteostasis axis: implications in neurodegenerative diseases.Philosophical transactions of the Royal Society of London. Series B, Biological sciences · 2026Review
- Gut microbial community of patients with Parkinson's disease analyzed using metagenome-assembled genomes.Neural regeneration research · 2026Article
- Akkermansia muciniphila : A next-generation gut probiotic supporting neurorepair and functional recovery.Neural regeneration research · 2026Article
- Integrated Metagenomic and Metabolomic Profiling Identifies Severity-Specific Gut Microbiota Signatures Across A-B-E Phenotypes in Clinically Stable COPD: A Cross-Sectional Study.Microorganisms · 2026Article
- Possible Mechanisms Underlying the Effects of Fecal Microbiota Transplantation in Patients With Irritable Bowel Syndrome.Journal of neurogastroenterology and motility · 2026Article
310 more citing papers are in PubMed but not listed here.
Corrections and comments
- Erratum issued
Authors and funding
8 authors at 4 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundParkinson's disease (PD) presently is conceptualized as a protein aggregation disease in which pathology involves both the enteric and the central nervous system, possibly spreading from one to another via the vagus nerves. As gastrointestinal dysfunction often precedes or parallels motor symptoms, the enteric system with its vast diversity of microorganisms may be involved in PD pathogenesis. Alterations in the enteric microbial taxonomic level of L-DOPA-naïve PD patients might also serve as a biomarker.
methodsWe performed metagenomic shotgun analyses and compared the fecal microbiomes of 31 early stage, L-DOPA-naïve PD patients to 28 age-matched controls.
resultsWe found increased Verrucomicrobiaceae (Akkermansia muciniphila) and unclassified Firmicutes, whereas Prevotellaceae (Prevotella copri) and Erysipelotrichaceae (Eubacterium biforme) were markedly lowered in PD samples. The observed differences could reliably separate PD from control with a ROC-AUC of 0.84. Functional analyses of the metagenomes revealed differences in microbiota metabolism in PD involving the ẞ-glucuronate and tryptophan metabolism. While the abundances of prophages and plasmids did not differ between PD and controls, total virus abundance was decreased in PD participants. Based on our analyses, the intake of either a MAO inhibitor, amantadine, or a dopamine agonist (which in summary relates to 90% of PD patients) had no overall influence on taxa abundance or microbial functions.
conclusionsOur data revealed differences of colonic microbiota and of microbiota metabolism between PD patients and controls at an unprecedented detail not achievable through 16S sequencing. The findings point to a yet unappreciated aspect of PD, possibly involving the intestinal barrier function and immune function in PD patients. The influence of the parkinsonian medication should be further investigated in the future in larger cohorts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.